Arboretum Ventures
VC Fund
Ann Arbor, United States
Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.
- Total investments:
- 117
- Last investment:
- Lead investor:
- 46%
- Fund size:
- $250M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Arboretum Ventures invests in
Stages Arboretum Ventures invests in
Countries Arboretum Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $4.4M–$27M
- Series B
- $5M–$55M
- Series C
- $10M–$80M
Investment Focus
Industry
- Health Care 55 (47%)
- Medical 28 (24%)
- Biotechnology 28 (24%)
- Medical Device 24 (21%)
- Pharmaceutical 9 (8%)
Stage
- Series B 29 (25%)
- Series A 27 (23%)
- Series C 19 (16%)
- Series D 11 (9%)
- Funding Round 8 (7%)
Country
- United States 63 (54%)
- Canada 1 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Paul McCreadie
Managing Partner and Chief Operating Officer
|
Managing Partner and Chief Operating Officer | Total investments: 11 | Find email | |
Robert Cesaro
Associate
|
Associate | Total investments: 6 | Find email | |
Tim Petersen
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 18 | Find email | |
Amanda Goldstein
Executive Assistant
|
Executive Assistant | Total investments: 0 | Find email | |
George Dunbar
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D. | $50M / Series C / Mar 25, 2026 | ||
| Pharaoh Neuro develops a neurapheresis cerebrospinal fluid management system for neurological patients. | $20M / Series A / Feb 18, 2026 | ||
| Boomerang Medical is a female-led bioelectronic medical technology firm that is revolutionizing the management of autoimmune illnesses. | $20M / Series B / Sep 04, 2025 | ||
| Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $61M / Series B / Aug 13, 2025 | ||
| Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M / Series D / Jun 05, 2025 | ||
| Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other relatedareas.Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States. | $20M / Jun 03, 2025 | ||
| Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $40M / Series E / Mar 10, 2025 | ||
| Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored insterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects. | $80M / Series C / Jan 07, 2025 | ||
| Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M / Series D / Oct 08, 2024 | ||
| RareCyte is a provider of precision biology solutions that delivers platforms and services in both spatial biology and liquid biopsy. It offers tissue-based imaging tools under the Orion Spatial Biology suite, including imaging instruments and panels enabling multiplexed biomarker analysis in a single scan, and supplies rare cell analysisinstruments and consumables such as the CyteFinder II imaging systems, CytePicker module, AccuCyte sample preparation, and RarePlex panel kits for circulating tumor cell (CTC) detection and characterization. Additionally, RareCyte extends its offering with precision biology services encompassing custom assay development, clinical trial sample testing, and data analysis. | $20M / Venture - Series Unknown / Jun 27, 2024 | ||
| See all 117 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Arboretum Ventures invest in?
Arboretum Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 117 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arboretum Ventures's check size?
Arboretum Ventures typically joins rounds of $4.4M–$27M at Series A, $5M–$55M at Series B and $10M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arboretum Ventures participates in.
How do I contact Arboretum Ventures?
Public channels for Arboretum Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arboretum Ventures?
The team at Arboretum Ventures includes Paul McCreadie (Managing Partner and Chief Operating Officer), Robert Cesaro (Associate) and Tim Petersen (Founder and Managing Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
